Have a personal or library account? Click to login
Blood component administration to multiple myeloma patients treated with daratumumab: suggesting a novel approach with use of 0.1 M dithiothreitol Cover

Blood component administration to multiple myeloma patients treated with daratumumab: suggesting a novel approach with use of 0.1 M dithiothreitol

Immunohematology
Volume 36 (2020): Issue 4 (December 2020)
By: P. Pandey,  D. Setya,  E. Kaul,  S. Ranjan,  M.K. Singh and  A. Shankar  
Paid access
|Jan 2020

Authors

P. Pandey

Department of Transfusion Medicine, Noida, India

D. Setya

setyadivya@gmail.com

Department of Transfusion Medicine, Noida, India

E. Kaul

Department of Hemato-Oncology and BMT, Noida, India

S. Ranjan

Department of Transfusion Medicine, Noida, India

M.K. Singh

Department of Transfusion Medicine, Noida, India

A. Shankar

Department of Transfusion Medicine, Noida, India
DOI: https://doi.org/10.21307/immunohematology-2020-056 | Journal eISSN: 1930-3955 | Journal ISSN: 0894-203X
Journal RSS Feed
Language: English
Page range: 157 - 165
Published on: Jan 1, 2020
Published by: American National Red Cross
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
DARA,
daratumumab,
CD38,
DTT,
multiple myeloma,
hemolysis
Related subjects:
Medicine,
Clinical medicine,
Laboratory medicine

© 2020 P. Pandey, D. Setya, E. Kaul, S. Ranjan, M.K. Singh, A. Shankar, published by American National Red Cross
This work is licensed under the Creative Commons License.

Previous articleVolume 36 (2020): Issue 4 (December 2020)